{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.279","value":"-0.16"},{"groupId":"OG001","spread":"0.337","value":"-0.19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"201"}],"units":"Participants"}],"description":"The EQ-5D is a generic, multidimensional, health status instrument. The profile allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale \\[1 (no problem), 2 (some problems), and 3 (major problems)\\]. These combinations of responses were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status.","dispersionType":"Standard Deviation","groups":[{"description":"8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.","id":"OG000","title":"Ramucirumab (IMC-1211B) Plus Paclitaxel"},{"description":"Placebo was administered by IV infusion on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered on Days 1, 8, and 15 of a 28-day cycle.","id":"OG001","title":"Placebo Plus Paclitaxel"}],"paramType":"MEAN","populationDescription":"All participants according to the treatment group to which they were randomized with baseline and end of treatment EQ-5D observations.","reportingStatus":"POSTED","timeFrame":"Baseline, end of therapy (up to 103 weeks)","title":"Change From Baseline to End of Therapy in European Quality of Life Questionnaire-5 Dimension (EuroQol EQ-5D) Index Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}